Phase 3 Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Posoleucel (ALVR105) in Adenovirus Infection After Allogeneic Hematopoietic Cell Transplantation

Phase 3, randomised, double-blind trial in adenoviral infection comparing Posoleucel arm with Placebo arm (2 arms). Primary endpoints: Proportion of participants with undetectable viremia at Day 29 and Proportion of participants who develop target organ adenovirus disease or whose target organ disease progresses. Started Oct 2021; status: terminated.